HCR Wealth Advisors Takes Position in Eli Lilly And Co (NYSE:LLY)

HCR Wealth Advisors bought a new stake in shares of Eli Lilly And Co (NYSE:LLY) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 1,329 shares of the company’s stock, valued at approximately $217,000.

Several other institutional investors have also added to or reduced their stakes in LLY. Jennison Associates LLC raised its position in shares of Eli Lilly And Co by 125.9% during the 1st quarter. Jennison Associates LLC now owns 10,192,052 shares of the company’s stock valued at $1,413,841,000 after acquiring an additional 5,679,574 shares in the last quarter. BlackRock Inc. raised its position in shares of Eli Lilly And Co by 5.6% during the 1st quarter. BlackRock Inc. now owns 64,299,477 shares of the company’s stock valued at $8,919,623,000 after acquiring an additional 3,420,265 shares in the last quarter. APG Asset Management N.V. raised its position in shares of Eli Lilly And Co by 668.1% during the 1st quarter. APG Asset Management N.V. now owns 2,660,838 shares of the company’s stock valued at $307,495,000 after acquiring an additional 2,314,410 shares in the last quarter. Capital World Investors raised its position in shares of Eli Lilly And Co by 128.4% during the 1st quarter. Capital World Investors now owns 3,034,849 shares of the company’s stock valued at $420,994,000 after acquiring an additional 1,706,354 shares in the last quarter. Finally, Nuveen Asset Management LLC raised its position in shares of Eli Lilly And Co by 37.2% during the 1st quarter. Nuveen Asset Management LLC now owns 5,654,616 shares of the company’s stock valued at $784,408,000 after acquiring an additional 1,533,024 shares in the last quarter. Institutional investors own 77.32% of the company’s stock.

LLY stock traded down $2.71 during trading hours on Friday, hitting $150.29. 5,342,109 shares of the stock traded hands, compared to its average volume of 2,630,266. The stock has a 50-day simple moving average of $160.88 and a 200 day simple moving average of $148.62. Eli Lilly And Co has a one year low of $101.36 and a one year high of $170.75. The company has a market cap of $143.74 billion, a P/E ratio of 24.40, a P/E/G ratio of 1.32 and a beta of 0.26. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 4.37.

Eli Lilly And Co (NYSE:LLY) last announced its earnings results on Thursday, July 30th. The company reported $1.89 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.58 by $0.31. Eli Lilly And Co had a return on equity of 200.78% and a net margin of 24.48%. The business had revenue of $5.50 billion during the quarter, compared to analysts’ expectations of $5.77 billion. During the same quarter last year, the business posted $1.50 earnings per share. The company’s quarterly revenue was down 2.4% on a year-over-year basis. Analysts forecast that Eli Lilly And Co will post 7.3 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a $0.74 dividend. The ex-dividend date of this dividend is Thursday, August 13th. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.97%. Eli Lilly And Co’s dividend payout ratio (DPR) is 49.01%.

In related news, SVP Alfonso G. Zulueta sold 17,000 shares of the stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $162.94, for a total value of $2,769,980.00. Following the completion of the transaction, the senior vice president now owns 39,646 shares in the company, valued at approximately $6,459,919.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Lilly Endowment Inc sold 12,961 shares of the stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $169.69, for a total value of $2,199,352.09. Following the completion of the transaction, the insider now owns 111,132,563 shares of the company’s stock, valued at approximately $18,858,084,615.47. The disclosure for this sale can be found here. Insiders sold a total of 555,236 shares of company stock valued at $91,393,391 in the last quarter. 0.09% of the stock is currently owned by corporate insiders.

Several equities research analysts recently issued reports on LLY shares. UBS Group lowered Eli Lilly And Co from a “buy” rating to a “neutral” rating and upped their price target for the company from $157.00 to $158.00 in a research report on Monday, April 20th. Morgan Stanley lowered Eli Lilly And Co from an “overweight” rating to an “equal weight” rating in a report on Sunday, April 19th. Mizuho raised their price target on Eli Lilly And Co from $155.00 to $164.00 and gave the company a “neutral” rating in a report on Monday, June 29th. Zacks Investment Research lowered their price target on Eli Lilly And Co to $156.00 in a report on Wednesday, April 29th. Finally, JPMorgan Chase & Co. raised their price target on Eli Lilly And Co from $175.00 to $190.00 and gave the company an “overweight” rating in a report on Wednesday, June 17th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $168.58.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: Balanced Fund

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.